{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:04:55Z","timestamp":1773151495087,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1093\/ndt\/gfh930","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:53:28Z","timestamp":1118807608000},"page":"1813-1820","source":"Crossref","is-referenced-by-count":63,"title":["Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study"],"prefix":"10.1093","volume":"20","author":[{"given":"Tyree H.","family":"Kiser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas N.","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilee D.","family":"Obritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,6,14]]},"reference":[{"key":"key\n\t\t\t\t20171012200221_BIB1","doi-asserted-by":"crossref","unstructured":"Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology1993; 105: 229\u2013236","DOI":"10.1016\/0016-5085(93)90031-7"},{"key":"key\n\t\t\t\t20171012200221_BIB2","doi-asserted-by":"crossref","unstructured":"Rimola A, Gavaler JS, Schade RR et al. Effects of renal impairment on liver transplantation. Gastroenterology1987; 93: 148\u2013156","DOI":"10.1016\/0016-5085(87)90327-1"},{"key":"key\n\t\t\t\t20171012200221_BIB3","doi-asserted-by":"crossref","unstructured":"Restuccia T, Ortega R, Guevara M et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case\u2013control study. J Hepatol2004; 40: 140\u2013146","DOI":"10.1016\/j.jhep.2003.09.019"},{"key":"key\n\t\t\t\t20171012200221_BIB4","doi-asserted-by":"crossref","unstructured":"Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology1996; 23: 164\u2013176","DOI":"10.1002\/hep.510230122"},{"key":"key\n\t\t\t\t20171012200221_BIB5","doi-asserted-by":"crossref","unstructured":"Brooks DP, Share L, Crofton JT. Central adrenergic control of vasopressin release. Neuroendocrinology1986; 42: 416\u2013420","DOI":"10.1159\/000124480"},{"key":"key\n\t\t\t\t20171012200221_BIB6","doi-asserted-by":"crossref","unstructured":"Guevara M, Gines P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology1998; 27: 35\u201341","DOI":"10.1002\/hep.510270107"},{"key":"key\n\t\t\t\t20171012200221_BIB7","doi-asserted-by":"crossref","unstructured":"Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology1999; 30: 870\u2013875","DOI":"10.1002\/hep.510300430"},{"key":"key\n\t\t\t\t20171012200221_BIB8","doi-asserted-by":"crossref","unstructured":"Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol2000; 33: 43\u201348","DOI":"10.1016\/S0168-8278(00)80158-0"},{"key":"key\n\t\t\t\t20171012200221_BIB9","doi-asserted-by":"crossref","unstructured":"Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol2002; 14: 153\u2013158","DOI":"10.1097\/00042737-200202000-00009"},{"key":"key\n\t\t\t\t20171012200221_BIB10","doi-asserted-by":"crossref","unstructured":"Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology2002; 36: 941\u2013948","DOI":"10.1053\/jhep.2002.35819"},{"key":"key\n\t\t\t\t20171012200221_BIB11","doi-asserted-by":"crossref","unstructured":"Solanki P, Chawla A, Garg R et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol2003; 18: 152\u2013156","DOI":"10.1046\/j.1440-1746.2003.02934.x"},{"key":"key\n\t\t\t\t20171012200221_BIB12","doi-asserted-by":"crossref","unstructured":"Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology1999; 29: 1690\u20131697","DOI":"10.1002\/hep.510290629"},{"key":"key\n\t\t\t\t20171012200221_BIB13","doi-asserted-by":"crossref","unstructured":"Guevara M, Gines P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology1998; 28: 416\u2013422","DOI":"10.1002\/hep.510280219"},{"key":"key\n\t\t\t\t20171012200221_BIB14","doi-asserted-by":"crossref","unstructured":"Angeli P, Volpin R, Piovan D et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology1998; 28: 937\u2013943","DOI":"10.1002\/hep.510280407"},{"key":"key\n\t\t\t\t20171012200221_BIB15","doi-asserted-by":"crossref","unstructured":"Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology2004; 40: 55\u201364","DOI":"10.1002\/hep.20262"},{"key":"key\n\t\t\t\t20171012200221_BIB16","doi-asserted-by":"crossref","unstructured":"Pomier-Layrargues G, Paquin SC, Hassoun Z et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology2003; 38: 238\u2013243","DOI":"10.1053\/jhep.2003.50276"},{"key":"key\n\t\t\t\t20171012200221_BIB17","doi-asserted-by":"crossref","unstructured":"Dunser MW, Mayr AJ, Tur A et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med2003; 31: 1394\u20131398","DOI":"10.1097\/01.CCM.0000059722.94182.79"},{"key":"key\n\t\t\t\t20171012200221_BIB18","doi-asserted-by":"crossref","unstructured":"Obritsch MD, Jung R, Fish DN et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother2004; 38: 1117\u20131122","DOI":"10.1345\/aph.1D513"},{"key":"key\n\t\t\t\t20171012200221_BIB19","doi-asserted-by":"crossref","unstructured":"Malay MB, Ashton JL, Dahl K et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med2004; 32: 1327\u20131331","DOI":"10.1097\/01.CCM.0000128578.37822.F1"},{"key":"key\n\t\t\t\t20171012200221_BIB20","doi-asserted-by":"crossref","unstructured":"Moller S, Brinch K, Henriksen JH et al. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol1997; 26: 1026\u20131033","DOI":"10.1016\/S0168-8278(97)80111-0"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/20\/9\/1813\/5233731\/gfh930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:08:22Z","timestamp":1507853302000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/20\/9\/1813\/1850214\/Vasopressin-not-octreotide-may-be-beneficial-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,14]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,6,14]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfh930","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,9]]},"published":{"date-parts":[[2005,6,14]]}}}